Clinical Outcomes of Patients Receiving Fluoroquinolones to Treat Bacteremia Caused by Enterobacteriaceae Isolates Considered Intermediate or Resistant to These Agents According to the Recently Revised Susceptibility Testing Standards by the Clinical and Laboratory Standards Institute (CLSI).